Novocure announecs national reimbursement for Optune in Austria
Novocure has signed a contract with the Federation of the Austrian Social Insurance Institutions which grants reimbursement across Austria for Optune - Novocure's Tumor Treating Fields delivery system - for the treatment of adults with newly diagnosed glioblastoma. All 18 Austrian insurance funds have agreed to participate in the contract. With a defined reimbursement pathway now established in Austria, Novocure's efforts will turn to increasing adoption. Novocure estimates approximately 280 people are diagnosed with GBM or tumors that typically progress to GBM in Austria each year. Of this population, Novocure estimates that approximately 210 patients are candidates for treatment with Optune based upon the rate of disease progression and medical eligibility.